Leukemia Research
Volume 28, Issue 10 , Pages 1001-1004 , October 2004

Telomeres and telomerase in normal and leukemic hematopoietic cells

Received 14 January 2004 ,Accepted 19 January 2004.

References 

  1. Guo Y, Follo M, Geiger K, Lubbert M, Engelhardt M. Side-population cells from different precursor compartments. J. Hematother. Stem Cell Res. 2003;12:71–82
  2. Guo Y, Lubbert M, Engelhardt M. CD34-hematopoietic stem cells: current concepts and controversies. Stem Cells. 2003;21:15–20
  3. Elwood NJ. Telomere biology of human hematopoietic stem cells. Cancer Control. 2004;11(2):77–85
  4. Zakian VA. Telomeres: beginning to understand the end. Science. 1995;270:1601–1607
  5. Harley CB. Telomeres and aging. In: Blackburn EHG, Greider CW, editors. Telomeres. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1995, p. 247–65.
  6. Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H, et al.  Mammalian telomeres end in a large duplex loop. Cell. 1999;97:503–514
  7. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al.  Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–2015
  8. Weng NP, Levine BL, June CH, Hodes RJ. Human naive and memory T lymphocytes differ in telomeric length and replicative potential. Proc. Natl. Acad. Sci. U.S.A. 1995;92:11091–11094
  9. Cawthon RM, Smith KR, O’Brien E, Sivatchenko A, Kerber RA. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 2003;361:393–395
  10. Collins K. Telomere maintenance and disease. Lancet. 2003;362:983–988
  11. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al.  Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279:349–352
  12. Ramirez RD, Morales CP, Herbert BS, Rohde JM, Passons C, Shay JW, et al.  Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions. Genes Dev. 2001;15:398–403
  13. Henson JD, Neumann AA, Yeager TR, Reddel RR. Alternative lengthening of telomeres in mammalian cells. Oncogene. 2002;21:598–610
  14. van Steensel B, de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature. 1997;385:740–743
  15. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell. 1998;92:401–413
  16. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science. 1999;283:1321–1325
  17. Loayza D, de Lange T. POT1 as a terminal transducer of TRF1 telomere length control. Nature. 2003;424:1013–1018
  18. Karlseder J, Smogorzewska A, de Lange T. Senescence induced by altered telomere state, not telomere loss. Science. 2002;295:2446–2449
  19. Brummendorf TH, Holyoake TL, Rufer N, Barnett MJ, Schulzer M, Eaves CJ, et al.  Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood. 2000;95:1883–1890
  20. Engelhardt M, Silver RT, Drullinsky P, Mackenzie K, Moore MAS. Telomerase activity and telomere length primitive hematopoietic cells of acute and chronic leukemias at baseline and after ex vivo expansion. Cancer Res. 2000;60:610–617
  21. Adamson DJA, King DJ, Haites NE. Significant telomere shortening in childhood leukemia. Cancer Genet. Cytogenet. 1992;61:204–206
  22. Ohyashiki JH, Sashida G, Tauchi T, Ohyashiki K. Telomeres and telomerase in hematologic neoplasia. Oncogene. 2002;21:680–687
  23. Shay JW, Werbin H, Wright WE. Telomeres and telomerase in human leukemias. Leukemia. 1996;10:1255–1261
  24. Engelhardt M, Ozkaynak MF, Drullinsky P, Sandoval C, Tugal O, Jayabose S, et al.  Telomerase activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. Leukemia. 1998;12:13–24
  25. Franco S, Ozkaynak MF, Sandoval C, Tugal O, Engelhardt M, Moore MAS. Telomere dynamics in childhood leukemia and solid tumors: a follow-up study. Leukemia. 2003;17:401–410
  26. Ohyashiki JH, Ohyashiki K, Fujimura T, Kawakubo K, Shimamoto T, Iwabuchi A, et al.  Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res. 1994;54:3557–3560
  27. Boultwood J, Fidler C, Kusec R, Rack K, Elliott PJ, Atoyebi O, et al.  Telomere length in myelodysplastic syndromes. Am. J. Hematol. 1997;56:266–271
  28. Engelhardt M, Kumar R, Albanell J, Pettengell R, Han W, Moore MAS. Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood. 1997;90:182–193
  29. Martens UM, Brass V, Sedlacek L, Pantic M, Exner C, Guo Y, et al.  Telomere maintenance in human B lymphocytes. Br. J. Haematol. 2002;119:810–818
  30. Wynn RF, Cross MA, Hatton C, Will AM, Lashford LS, Dexter TM, et al.  Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet. 1998;351:178–181
  31. Rufer N, Brummendorf TH, Chapuis B, Helg C, Lansdorp PM, Roosnek E. Accelerated telomere shortening in hematological lineages is limited to the first year following stem cell transplantation. Blood. 2001;97:575–577
  32. Engelhardt M, Finke J. Does telomere shortening count?. Blood. 2001;98:888–889
  33. Thornley I, Sutherland R, Wynn R, Nayar R, Sung L, Corpus G, et al.  Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss. Blood. 2002;99:2387–2396
  34. Legare RD, Gribben JG, Maragh M, Hermanowski-Vosatka A, Roach S, Tantravahi R, et al.  Prediction of therapy-related acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) after autologous bone marrow transplant (ABMT) for lymphoma. Am. J. Hematol. 1997;56:45–51
  35. Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood. 2000;95:3273–3279
  36. Nichols G, de Castro K, Wei LX, Griffin M, Lin N, Oratzi A, et al.  Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer. Leukemia. 2002;16:1673–1679
  37. Podesta M, Piaggio G, Frassoni F, Pitto A, Mordini N, Bregante S, et al.  Deficient reconstitution of early progenitors after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;19:1011–1017
  38. Awaya N, Baerlocher GM, Manley TJ, Sanders JE, Mielcarek M, Torok-Storb B, et al.  Telomere shortening in hematopoietic stem cell transplantation: a potential mechanism for late graft failure?. Biol. Blood Marrow Transplant. 2002;8:597–600
  39. Sieglova Z, Zilovcova S, Cermak J et al. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis. Leukemia Res, doi:10.1016/j.leukres.2003.11.020, this issue.

PII: S0145-2126(04)00059-1

doi: 10.1016/j.leukres.2004.01.015

Leukemia Research
Volume 28, Issue 10 , Pages 1001-1004 , October 2004

Article Tools